Patent · US Active

Ligand for orphan nuclear receptor Nur77 and uses thereof

US10808005B2 · kind B2 · utility

0Cited by

0References

11Claims

0Family size

Assignee

IXMEDICINE (XIAMEN) BIOLOGICAL TECHNOLOGY COMPANY LIMITED · CN

Inventors

Xiaokun Zhang · Xiamen, CN
Xiangzhi Lin · Xiamen, CN
Ying Su · San Diego, US
Zhiping Zeng · Shanghai, CN
Mengjie Hu · Xiamen, CN
Qiang LUO · Beijing, CN
Yi Zhu · Chengdu, CN
Alitongbieke Gulimiran · Xiamen, CN

Key dates

Filing date	Jul 4, 2017
Grant date	Oct 20, 2020
Priority date	—
Expiry date	Jul 4, 2037

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/912
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are use of a compound of Formula I as a ligand of orphan nulear receptor Nur77, and in the prevention or treatment of a orphan nulear receptor Nur77 associated disease,

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.